Values First Advisors Inc. Purchases 4,837 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Values First Advisors Inc. increased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 20.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,009 shares of the biopharmaceutical company’s stock after purchasing an additional 4,837 shares during the quarter. Values First Advisors Inc.’s holdings in Celldex Therapeutics were worth $733,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. Wellington Management Group LLP increased its position in Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock valued at $314,190,000 after purchasing an additional 1,167,659 shares during the period. Bellevue Group AG increased its position in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after buying an additional 100,000 shares during the period. Geode Capital Management LLC raised its stake in Celldex Therapeutics by 0.4% in the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock worth $52,372,000 after buying an additional 6,557 shares in the last quarter. Jennison Associates LLC lifted its holdings in Celldex Therapeutics by 32.0% in the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after buying an additional 321,325 shares during the period. Finally, Novo Holdings A S boosted its position in Celldex Therapeutics by 13.4% during the 3rd quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after acquiring an additional 113,663 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Stock Up 1.6 %

Celldex Therapeutics stock opened at $22.26 on Thursday. The stock’s 50 day moving average is $24.93 and its 200 day moving average is $30.08. The company has a market capitalization of $1.48 billion, a P/E ratio of -8.66 and a beta of 1.60. Celldex Therapeutics, Inc. has a twelve month low of $20.91 and a twelve month high of $53.18.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.